I don’t disagree with the quick money being a partnership. The second quickest could very well be mTNBC because of immediate open access sales if they were to accept our continued data without refilling the BTD. That could happen next week also.
There is 100 million per quarter market for Trodelvy who is our competition. I am thinking reputation is everything with better results than Trodelvy. I bet that the oncology providers are watching just because immune modulators and cancer are a pretty big deal for the last few years and changing the landscape of cancer treatment. As frequent as drugs are coming out… if your are not watching what is going on. You will be left in the dust.
Trodelvy was only approved last April and already tapped a recent quarter at 100 million… pretty impressive results straight out of the gate for Trodelvy. Maybe we tap that or maybe we get half that… still nice revenue that relieves the financial pressure we are feeling. I am hoping for the mTNBC BTD to come through for us first and revenue to fund our other trials. Meet our other financial requirements.
There is 100 million per quarter market for Trodelvy who is our competition. I am thinking reputation is everything with better results than Trodelvy. I bet that the oncology providers are watching just because immune modulators and cancer are a pretty big deal for the last few years and changing the landscape of cancer treatment. As frequent as drugs are coming out… if your are not watching what is going on. You will be left in the dust.
Trodelvy was only approved last April and already tapped a recent quarter at 100 million… pretty impressive results straight out of the gate for Trodelvy. Maybe we tap that or maybe we get half that… still nice revenue that relieves the financial pressure we are feeling. I am hoping for the mTNBC BTD to come through for us first and revenue to fund our other trials. Meet our other financial requirements.
1
